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From the Editor’s Desk
The second issue of 2018 is non-thematic. Apart
from sharing knowledge on glycated haemoglobin,
fecal calprotectin, Factor V clotting assay and
aplastic anaemia, we have also included a short
review of TNM classification of head and neck
cancers along with an article on radiology pathology
correlation. The contributing authors have written
an update on transfusion associated circulatory

overload with quick pointers on how to diagnose the
condition.
It is hoped that this issue will further enhance
the awareness and education of our physicians in
diagnosing common and rare medical conditions
Natasha Ali

Inappropriate Requesting Of Glycated
Haemoglobin (HBA1c) By Clinicians
Dr Faryal Husnain
Chemical Pathology

Seventy percent of patients’ management related
decisions are based on Laboratory testing but there
are no checks in place to measure appropriateness
of test ordering in our present clinical setup.
There exist a major quality gap, which leads to
clinicians ordering inappropriate tests or tests that
don’t necessarily help the patients’ diagnoses or
treatment plans. The HbA1c testing is one of its
example. This article will explain the appropriate and
inappropriate utilization of the HBA1c testing in the
light of latest international guidelines by American
Diabetic Association (ADA) so that our resources
can be better utilized to serve our patients and avoid
unnecessary tests.
The HBA1c is a glycated variant of Hemoglobin-A
resulting from non-enzymatic attachment of various
carbohydrates to valine in N-terminal of the betachain of Haemoglobin, which exists under normal
physiological conditions. Glucose can attach to
other sites as well but HBA1c is the most abundant
glycated species. Since the protein is located inside
the erythrocytes, glycation is related to the lifespan
of erythrocytes. HbA1c provides an estimate of mean
blood glucose over the lifespan of the erythrocyte
(3–4 months).
This variant increases considerably in concentration
in patients with uncontrolled blood glucose levels
and is used to diagnose and monitor glycemic control
in Diabetes Mellitus and to predict the development

of microvascular complications in Diabetic patients.
HbA1c testing became commercially available
in the 1970s, but the clinical utility of HbA1c did
not become obvious until 1993 when the Diabetes
Control and Complications Trial (DCCT) was
published. This trial proved the association between
HbA1c and diabetes complications and resulted in
specific treatment goals for people with diabetes.
Based on the DCCT, the ADA recommended
routine measurement of HbA1c with specific
targets to monitor glycemic control in diabetics.
The National Glycohemoglobin Standardization
Program (NGSP) was initiated in 1996 with the
goal of standardizing reported results to the to the
DCCT reference, regardless of the glycated species
measured, which resulted in a lot of improvement in
the comparability of results. This was followed by
World Health Organization (WHO), recommending
HbA1c as a criterion for the diagnosis of Diabetes
Mellitus in 2011.
Factors Causing Variation in HBA1c Results
The HBA1c can give skewed results in people
with certain conditions, such as hemolytic or other
anemia’s, sickle cell disease, use of drugs that
stimulate erythropoiesis, recent blood transfusion,
end-stage kidney disease, in people with hemoglobin
variants (HbS, HbF or HbG). Other factors that
can cause falsely elevated results are, uremia
3
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(BUN>85mg/dl), hypertriglyceridemia (>1,750mg/
dl), chronic alcohol consumption, high bilirubinemia
(>20mg/dl), chronic aspirin use and pregnancy
(2nd and 3rd trimester). According to the ADA
recommendations, HBA1C must be forgone if there
is disagreement between A1C and blood glucose
levels. In such cases, the clinician may consider
alternate diagnostic tests such as fasting plasma
glucose test or oral glucose tolerance test.
Thereby Clinicians need to be aware of these
limitations and assess whether HBA1c is
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adequate for monitoring a particular patient’s
glycemic control or when using A1C as the sole
basis for assessing glycemic control, particularly
if the result is close to medical decision level
thresholds. Patients should be assessed for the
factors that can affect HbA1c results, especially
in our population where certain aforementioned
conditions are common. In such cases glycemic
control is best evaluated by the combination of
results from HbA1c and serial or continuous
blood glucose monitoring using a point of care
device.

Antiglobulin Test
Dr Ruhul Quddus
Haematology & Transfusion Medicine

Antiglobulin test was first described in 1940s by
Coombs et al. and Boorman et al. to identify the
immune mediated nature of haemolysis. It simply
enhances the antibodies bound to the surface of red
blood cells that would not agglutinate on its own.
With the help of antihuman globulin or antiserum,
i.e., Coombs reagent, those sensitized red blood
cells agglutinate and, thus, verifying the immunemediated haemolysis.
Alternatively it is used for the identification of
antibodies by reacting a patient’s serum with red
cells of known antigenic signature. The former
method is known as ‘Direct (Coombs’) antiglobulin
test or DAT’ (2, 3) while the latter, which is more
commonly used, is known as ‘Indirect (Coombs’)
antiglobulin test or IAT’ (1). It is a quick, cheap and
inexpensive test producing very useful information.
However, the predictive value of a positive DAT for

4

determining whether or not a patient has immune
hemolytic anemia is 83% in a patient with hemolytic
anemia but only 1.4 percent in a patient without
hemolytic anemia. So, before interpreting DAT the
clinical and laboratory evidence of haemolysis needs
to be established.
Direct antiglobulin test is valuable in diagnosis
of: (a) autoimmune hemolytic anaemia; (b) druginduced immune haemolytic anaemia; (c) haemolytic
transfusion reactions due to alloantibodies; and (d)
hemolytic disease of the fetus and newborn.
Indirect antiglobulin test is useful for: (a) detection
of antibodies in serum, i.e., antibody screening &
identification, and crossmatching; (b) detection of
antibodies in eluates prepared from sensitized RBCs;
and (c) typing of RBCs when testing for weak D
phenotypes.
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Fecal Calprotectin (S100a8/S100a9)
Dr Siraj Munir
Chemical Pathology

Calprotectin, is a member of the S100 calciumbinding protein family, formed as a heterodimer
of S100A8 and S100A9. It is expressed mainly by
granulocytes and, to a lesser extent, by epithelial
cells and macrophages/monocytes. In neutrophils,
approximately 60 percent of the total cytoplasmic
protein content is made up of calprotectin.
Activation of the intestinal immune system results
in recruitment of neutrophils. Cellular proteins,
including calprotectin are released from these
neutrophils after their activation. These proteins limit
the growth of bacteria and fungi by sequestering
manganese and zinc.
Eventually calprotectin enters the lumen of the gut
after translocation across the epithelial barrier. With
the progress of inflammatory process, the fecal
material absorbs the released calprotectin before it is
excretion from the body. The amount of calprotectin
present in the feces is proportional to the number
of neutrophils within the gastrointestinal mucosa
and can be used as an indirect marker of intestinal
inflammation.

Calprotectin is a marker to diagnose or monitor
IBD, presently considered a gold standard,
included in clinical practice guidelines and its
levels correlate with the severity of IBD. Increased
levels of fecal calprotectin may be helpful in
distinguishing Inflammatory Bowel Disease (IBD)
from functional gastrointestinal disorders, such as
irritable bowel syndrome (IBS). Calprotectin is
observed to perform better in predicting ulcerative
colitis then Chron’s disease. Fecal calprotectin has
sensitivity and specificity both of approximately
85 percent, for this differential diagnosis. Metaanalysis have reported that calprotectin perform
better in adults (sensitivity 93 percent & specificity
96 percent) than children (sensitivity 92 percent
& specificity 76 percent). However, it must be
kept in mind that elevated concentrations of fecal
calprotectin are not diagnostic for IBD, as other
disorders such as colorectal cancer, gastrointestinal
infections and celiac disease may also be associated
with neutrophilic inflammation.

Faecal
Calprotectin
Calprotectin ≤50
µg/g
Likely functional
gastrointestinal
disorders

Calprotectin 50-120
µg/g
Mild inflammatory
process: treated IBD
or infection,
NSAIDS/Asprin/PPI
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Retesting in 6 to 6
weeks

Calprotectin ≤50
µg/g
noninflammatory
condition

Calprotectin ≥120
µg/g
Active
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the GI system
Further diagnostic
testing is required

Calprotectin >50
µg/g
suggest
colonoscopy

Figure 1: Algorithmic approach to a patient suspected with Inflammatory Bowel Disease (Adapted from: Faecal markers of gastrointestinal inflammation.
July 2012Journal of clinical pathology 65(11):981-5. DOI: 10.1136/jclinpath-2012-200901)
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Calprotectin is resistant to bacterial degradation
in the gut and is stable in stool for up to one
week at room temperature and is readily

measured using immunochemical techniques.
Limitations and diagnostic accuracies are
conversed in table1.

Table 1: Clinical utility, Limitations, clinical sensitivity and specificity of
Fecal Calprotectin use.

Indication
Distinguishing functional from
organic bowel disease and
predicting relapse in IBD

Limitations

Sensitivity

Specificity

70-100%

70-100%

• Disease nonspecific
• Affected by age, comorbidities, NSAIDs use
• Day to day variations
• Miss low level inflammatory activity

Fecal Pancreatic Elastase: A Test for
Pancreatic Insufficiency
Dr Tayyaba Hassan
Chemical Pathology

Elastase is an enzyme produced by exocrine
tissue in the pancreas. The pancreas is an organ
located in the abdomen that consists of two kinds
of tissues: exocrine and endocrine. The exocrine
pancreas is responsible for producing elastase
along with other enzymes that are transported to
the small intestine to break down fats, proteins,
and carbohydrates as part of food digestion. This
test measures the amount of elastase in stool
(feces) to evaluate whether a person’s pancreas is
functioning properly.
Exocrine pancreatic insufficiency (PEI) causes
problems in food digestion, as the body is
unable to break down and absorb nutrients in the
absence of enzymes. When you have PEI, you
might lose weight or have pain in your abdomen
and can experience symptoms associated with
malabsorption and, in severe cases, symptoms of
malnutrition which can in turn lead to anemia,
rickets or osteomalacia.
Fecal elastase is an enzymatic product of
pancreatic secretion that remains relatively stable
during transport through the gastrointestinal
tract. The fecal elastase-1 reflects the secretory
capacity of the pancreas. The elastase test
is usually done when a person has signs and
symptoms of pancreatic insufficiency e.g.
6

abdominal cramps, bloating, foul-smelling,
bulky or greasy stools, in children; inability
to gain weight, delayed growth, malnutrition,
vitamin deficiencies and weight loss. The test
is also used in assessing exocrine pancreatic
function in cystic fibrosis, diabetes mellitus, or
chronic pancreatitis. Fecal Elastase at Aga Khan
clinical laboratories is done by Enzyme linked
immunosorbent assay (ELISA) and decreased
amount indicates that the person has pancreatic
insufficiency. The stool sample should be formed
(not watery) and not contaminated with urine or
water. The test may show false low results if the
sample of stool is watery, such as with diarrhea
as the water in the stool will dilute the elastase
and decrease the amount measured. If patient
is taking pancreatic enzymes, they should be
discontinued for five days before taking stool
sample.
Fecal Elastase test is a reliable test for the
assessing pancreatic function in many pancreatic
and non-pancreatic diseases. It is non-invasive,
give results in short duration, and is not affected
by pancreatic enzyme replacement therapy. It is a
useful test for screening of patients who may be
at risk of pancreatic dysfunction.
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Clinical suspicion
of PEI
Evaluation of serum
nutritional markers
and fecal elastase
Fecal elastase < 50

Fecal elastase 15-200
or > 15 with
abnormal nutritional
markers

Fecal elastase < 200
and normal
nutritional panel

MPD dilatation or
calcifications on imaging?
High probability of PEI

Yes

No

Low probability of PEI

Figure 1: Diagnostic approach of suspected pancreatic exocrine insufficiency (Source: Lindkvist B. Diagnosis and treatment of pancreatic exocrine
insufficiency. World J Gastroenterol 2013; 19(42): 7258-7266)

Factor V Clotting Factor Assay Instead of Factor
V Leiden Assay (Activated Protein C Resistance)
As A Part of Thrombophilia Screening;
A Misconception to be Re-Conceptualized
Dr. Farrukh Zia
Clinical Haematology

Factor V Leiden ((FVL)) is a mutant coagulation
factor V. The FVL mutation causes insensitivity
of factor V (both the activated and inactive forms)
to the actions of activated protein C (aPC), a
natural anticoagulant. As a result, individuals who
inherit the FVL mutation have high risk of venous
thromboembolism. FV Leiden-induced APC
resistance accounts for 20 percent of unselected
patients with first-episode thrombosis, 50
percent of familial thrombosis, and 60 percent of
thrombotic patients known to have normal levels
of protein S, protein C, anti-thrombin, and antiphospholipid antibodies.
Figure 1: Mechanism of Action of Activated protein C, rendering inactivation of Factor V
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Circumstantial risk factors for VTE in Leiden variant
heterozygotes or homozygotes are summarized in
following table 1,
Circumstance

Relative Risk for VTE

Unknown: probably modest
2x-3x ↑ relative risk
Central venous catheter use 5x ↑ relative risk in those
w/cancer
2x ↑ relative risk
8x ↑ relative risk when traveling
Travel
≥4 uninterrupted hours
23x-50x ↑ risk
Minor leg injury
After age 45 years lifetime risk =
Age
17% (vs 8% in general
population)
Oral HRT
7x-25x ↑ relative risk
Obesity (BMI >30 kg/m2) 5x-12x ↑ relative risk
Malignancy

Rodger et al 2010 evaluated in a study of prospective
cohort that there is a slightly increased risk of
pregnancy loss in women with the Leiden variant
(4.2 percent) compared to those without the variant
(3.2 percent) (odds ratio 1.52).
Scenario in Pakistan
In Pakistan, thrombo-embolic events due to inherited
or acquired thrombophilias are not very uncommon.
In a study conducted by Nadir et al in Rawalpindi,
overall FVL mutation was observed in 14.5 percent
patients of thrombophilia. It was detected in five

percent patients of CVA, nine percent in PE, 33
percent in DVT and 17 percent in PV patients. In
another study conducted by Khalid et al at AKUH,
FVL mutation was detected in 14.2 percent patients
suffering thromboembolism.
Discussion
There is a common misconception in our health
professionals while screening the patients for
thrombophilias that they advise Factor V clotting
factors assay instead of Factor V Leiden (Activated
protein resistance) which results in wastage of
resources as well as cost burden over the patients. It
also causes delay in the patient diagnosis and proper
management.
In the month of July 2018 in Aga khan Hospital,
Karachi total of 476 samples were received for
thrombophilia screening including Protein S, Protein
C, Antithrombin III and Homocysteine levels. The
request for Factor V Leiden was found in 74 samples
while 17 samples were mistakenly labelled for Factor
V clotting factor Assay.
Hence, there is a need to develop awareness and
educate our health professionals regarding this
important issue in order to solve the problem.
Efforts can be made collectively through on line
interactive sessions, publications, conducting
CME’s, distribution and availability of education
material and brochures on collection point of labs,
clinics and hospitals.

A Short Review of the Major Changes in the
TNM Classification of Head and Neck Cancers
in The American Joint Committee on Cancer
Eighth Edition of Cancer Staging Manual
Dr Sabeehuddin Siddique
Histopathology

Introduction
Cancer staging is an important component of patient
care across the world. The primary purpose of TNM
system is to provide an anatomic-based classification
8

to adequately depict cancer prognosis and treatment
outcome. To maintain clinical relevance, AJCC
(American Joint Committee on Cancer) periodically
revises and updates the TNM Classification. The
latest (8th) edition of AJCC Cancer staging manual
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carries some major changes in the criteria of head
and neck cancer staging and the most important ones
are discussed here.
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Table 2. Definition of the T category in the 8th edition TNM for cancer of
oral cavity, soft tissue sarcoma of the head and neck cutaneous
carcinoma of the head and neck

New TNM Classifications
HPV-mediated (p16+) Oropharyngeal
Carcinoma (OPC) : In response to an urgent need
to properly depict the character and prognosis
of this recently described disease, a new staging
system has been introduced for HPV-positive OPC
in the 8th edition TNM (Table 1). It is also for the
first time that separate clinical and pathological
N-definitions and T-N groupings have been
introduced in the HNC classification. The clinical
staging system has been based on the proposal of
the International Collaboration on Oropharyngeal
cancer Network group.
Table 1. The 8th edition clinical and pathologic TNM
classification for the HPV-mediated oropharyangeal cancer

(Adapted from Shao H Huang and Brian O’ Sullivan. Overview of the 8th
edition TNM classification for head and neck cancer. Curr Treat Options
in Oncol. (2017) 18: 40)

Head and Neck Soft Tissue Sarcoma (HNSTS): It is another new classification introduced
in the 8th edition TNM. In the previous edition
HN-STS used the same TNM classification as
soft tissue sarcomas of other sites. Although
they are biologically similar, HN-STS present
some unique characteristics. The traditional
5-cm size cut-point separating T1 and T2 soft
tissue sarcomas of the extremity and trunk lacks
relevance for HN-STS since the majority of
patients in recent studies do not even reach the
5 cm cut-off. In this edition, the 2 cm and 4 cm
breakpoint for T category was arbitrarily chosen
based on traditional HNC size criteria; T1 ≤2
cm, T2 >2 to ≤4c cm, and T4 for very extensive
tumours (Table 2).

(Adapted Shao H Huang and Brian O’ Sullivan. Overview of the 8th
edition TNM classification for head and neck cancer. Curr Treat Options
in Oncol. (2017) 18: 40)

Head and Neck Carcinoma of Unknown Primary
and Modification of N Categories (inclusion of
the extranodal extension): An independent chapter
describing the principles of Carcinoma of Unknown
Primary (CUP) in head and neck has been introduced
in the AJCC Staging Manual. T0 will be assigned for
all CUPs for EBV-positive CUP and HPV-positive
CUP, the N classification follows nasopharyngeal
carcinoma and HPV-positive OPC definitions
respectively and requires biological assessments
to direct their assignations. For the remainder
N classification is instituted by inclusion of the
extranodal extension variable. Since its presence has
been shown to have independent adverse prognostic
impact for non-viral related head and neck carcinoma
(Table 3).
Table 3. The 8th edition N classification for non-viral related head and
neck cancer and stage grouping for viral and non-viral unknown primary
- cervical nodes

(Adapted from Shao H Huang and Brian O’ Sullivan. Overview of the 8th
edition TNM classification for head and neck cancer. Curr Treat Options
in Oncol. (2017) 18: 40)

Notably, inclusion of extranodal extension is
included in both clinical and pathological staging,
9
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not only for CUP but also for all non-viral related
head and neck carcinomas, including salivary gland
malignancies, with the exception of melanoma, soft
tissue sarcomas, and thyroid cancer. Since several
studies have shown that CT or MRI cannot reliably
determine the presence of extranodal extension,
therefore the criteria of clinical extranodal extension
is however different from that of the pathological
one and only refers to those unambiguous clinical/
radiological evidence of gross extranodal extension,
such as dermal involvement or soft tissue invasion
with deep tethering to underlying muscle, adjacent
structures or clinical signs of nerve involvement.
From pathologic perspective, soft tissue deposits in
the lymphatic drainage pathways without identifiable
lymph node(s) would be recorded as positive LN
with positive extranodal extension because it would
represent a LN totally replaced by metastatic deposit.
MODIFICATION OF ‘T’ AND ‘N’
CATEGORIES
Nasopharyngeal carcinoma--modification of the
T and N categories: In comparison to the previous
edition of the AJCC Manual, notable changes have
been introduced to the ‘T’ and ‘N’ categories of
nasopharyngeal carcinoma in the 8th edition of
AJCC Manual (Table 4). The These changes have
Table 4. Change of the T and N categories in the 8th edition compared to
7th edition TNM classification for nasopharyangeal cancer

(Adapted from Shao H Huang and Brian O’ Sullivan. Overview of the 8th
edition TNM classification for head and neck cancer. Curr Treat Options
in Oncol. (2017) 18: 40)

resulted from more accurate imaging permitting
better delineation of tumour extent and early
detection of occult metastases linked to advances in

10

VOL. 44, ISSUE 1

radiotherapy with increasing conformity of tumour
coverage and sparing of uninvolved structures and by
the contemporary use of combination chemotherapy
that improves tumour control and cure rates,
especially for advanced loco-regional disease. Two
prognostic factors that were previously listed under
the nasopharyngeal carcinoma staging and which
have been eliminated from the 8th edition of AJCC
Manual are pre-treatment plasma EBV-DNA copy
number and gross tumour volume. The EBV-DNA
copy number has been omitted due to the challenges
arising from the feasibility and practicality of the test
and also because of lack of standardization of testing
methods between laboratories. The Gross tumour
volume has been deleted due to the paucity of data
on the reliability and practicality in deriving this
parameter by radiologists.
Oral squamous cell carcinoma—modification of
the T categories (inclusion of depth of invasion):
Depth of invasion (DOI) or tumour thickness is
another dimension of tumour size that likely reflects
the proximity to underlying lymph-vascular structures.
It has been reported as a good predictor of the
presence of pathologic overt LNs. The definition
of ‘T’ categories for oral cavity cancers using cutoffs of 0.5 and 1.0 cm for T1, T2 and T3 tumours,
respectively, according to the following criteria T1: ≤2
cm in maximum size and ≤0.5 cm in DOI; T2: ≤2 cm
in maximum size with DOI between 0.5–1.0 cm, or
2–4 cm sized lesion and DOI ≤1.0 cm; and T3: >4 cm
in size or any tumour with DOI >1.0 cm (Table 2).
Head and neck cutaneous carcinoma—
modification of T category (reintroduction of
tumour size criteria): In the non-merkel cell
cutaneous carcinoma of the head and neck chapter
of the 8th edition of AJCC Manual, size criteria
were reintroduced for ‘T’ classification because
many studies have shown a strong correlation
between the tumour size and more biologically
aggressive behavior of disease. The cut-off point for
primary size is now in line with other mucosal head
and neck squamous cell carcinomas where a ≤ 2 cm
primary is classified as T1 and a 2–4 cm primary
is classified as T2, a larger tumour (>4 cm) or with
other high-risk features is classified as T3 (DOI
> 0.6 cm or peri-neural invasion or minor bone
erosion) or T4 (major invasion of bone or skull
base).
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Radiology Pathology Correlation
Dr Nasir Ud Din and Dawar Khan
Histopathology and Radiology

A 21 year old male presented with left shoulder
pain. X-ray was obtained which showed focal lesion
having popcorn type of calcification in left humeral
proximal end.

Figure 2A,B: Low and high power shows lobules of hyaline cartilage.

Figure 1: Anteroposterior view shows well defined focal lesion with
popcorn type of calcification in left humeral proximal end.

Enchondromas are relatively common benign cartilage
tumours. Majority of patients present within two
to five decades of life. Tumour most commonly
involves small tubular bones of hand (approx. 40
percent). In long bones, proximal humerus, distal tibia,
proximal and distal femur is commonly involved.
Clinical presentation is swelling with or without pain.
Radiologically, enchondromas are benign mostly
medullary lytic lesion in long bones with rings, arcs
and popcorn type of calcification. Usually it has no
periosteal reaction or no soft tissue mass.
Radiological differential diagnosis in long bones is bone
infarct. Bone infarcts tend to have a well-circumscribed,
sclerotic margin. Calcification in bone infarct is
geographical in appearance and denser. Histologically,
increase cellularity and binucleation is seen in tumours
of digits and those occurring in syndromes which may
cause confusion with chondrosarcoma. However, host
bone permeation is not seen.

The tumour was curetted and histological
examination showed circumscribed lobules of
hypocellular hyaline cartilage with peripheral
rim of reactive bone. No binucleation, mitosis or
host bone entrapment was seen. Final diagnosis
was Enchondroma after radiological-pathological
correlation.

Almost 90 percent of enchondromas are solitary.
Multiple lesions occur in syndromes: Ollier disease,
Maffucci syndrome and metachondromatosis.
Malignant transformation of isolated lesion into
chondrosarcoma is very rare. Increased incidence of
malignant transformation is seen in enchondromatosis.
Local recurrence following curettage is uncommon
(three-four percent). Local recurrence should raise
suspicion of chondrosarcoma.
11
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Myelodysplastic Syndromes (MDS)
Dr Qayyum Khan & Dr Anila Rashid
Hematology & Transfusion Medicine

The myelodysplastic syndromes (MDS) comprise
a heterogeneous group of malignant hematopoietic
stem cell disorders characterized by dysplastic
(figure1) and ineffective blood cell production. MDS
occur most commonly in older adults and may occur
de novo or arise years after exposure to potentially
mutagenic therapy (eg, radiation exposure,
chemotherapy).

Figure 1: Decreased nuclear lobes in myelodysplasia (pseudo Pelger-Huet
anomaly)

The diagnosis of MDS should be considered in
any patient with unexplained cytopenia(s) or
monocytosis. Careful inspection of the peripheral

blood smear and bone marrow aspirate is necessary
to document the requisite dysplastic cytologic
features identifiable in any or all of the hematopoietic
lineages [table 1].
Bone marrow aspirate provides material for a 500cell differential count to determine the percentage
of blasts in the marrow; it also allows for a detailed
cytologic evaluation of the blasts and other cells.
Impaired myeloid maturation is often readily
apparent. The percentage of granulocytic precursors
is variable, but more often decreased than increased,
and a relative maturation arrest may be seen at the
myelocyte stage. Maturation of the cytoplasm may
progress more rapidly than the nucleus.
The bone marrow biopsy gives a general overview
of the degree of involvement and specific histologic
features associated with the process.
Detection of certain chromosomal abnormalities by
routine cytogenetic analysis, reverse transcriptase
polymerase chain reaction (RT-PCR), or fluorescent
in situ hybridization (FISH) distinguishes between
MDS and acute myeloid leukemia (AML) in some
cases, aids in the classification of MDS, and is a
major factor in determining prognostic risk group
and therapy.

Table 1: Morphologic abnormalities in myelodysplastic syndrome

Lineage

12

Peripheral Blood

Bone Marrow

Erythroid

Anisocytosis
Poikilocytosis
Basophilic stippling
Nucleated red cells
Tear drop cells

Nuclear budding
Internuclear bridging
Karyorrhexis
Multinuclearity
Nuclear hyperlobation
Megaloblastic changes
Ring sideroblasts

Myeloid

Granulocyte nuclear hypolobation
(pseudo PelgerHüet)
Granulocyte cytoplasmic
hypo/degranulation Blasts

Nuclear hypolobation (pseudo Pelger-Hüet)
Irregular hypersegmentation Bizarre nuclear shapes
Decreased granules; agranularity
Pseudo Chediak-Higashi granules
Auer rods

Megakaryocytes

Platelet anisocytosis
Giant platelets

Micromegakaryocytes
Nuclear hypolobation
Dispersed nuclei
Degranulation
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The presence of one of the following chromosomal
abnormalities is presumptive evidence of MDS
in patients with otherwise unexplained refractory
cytopenia and no morphologic evidence of dysplasia.

●-5/del(5q)
●del(13q)
●del(11q)
●inv(3)(q21q26.2)

The presence of one of the following chromosomal
abnormalities is presumptive evidence of MDS
in patients with otherwise unexplained refractory
cytopenia and no morphologic evidence of dysplasia.
●-7/del(7q)

Myelodysplastic Syndrome Subtypes: WHO 2016

Dysplastic
Lineage

Name

The WHO classification system distinguishes
six general entities with the following estimated
percentages
Ring Sideroblasts as % of
Marrow Erythroid Elements

Cytopenias

Bone Marrow (BM)
Peripheral Blood (PB)
Blasts

MDS with single lineage
dysplasia

1

1 or 2

<15% / <5% (If SF3B1 mutation is
present)

MDS with multilineage
dysplasia

2 or 3

1-3

15%/, <5% (If SF3B1 mutation is present) BM <5%, PB <1%,
no Auer rods

MDS-RS with single
lineage dysplasia

1

1 or 2

≥15% / ≥5 (If SF3B1 mutation is present)

BM < 5%, PB < 1%,
no Auer rods

MDS-RS with
multilineage dysplasia

2 or 3

1-3

≥15% / ≥5%(If SF3B1 mutation is
present)

BM <5%, PB < 1%,
no Auer rods

MDS with isolated del(5q)

1-3

1-2

None or any

BM < 5%, PB < 1%,
no Auer rods

MDS-EB-1

0-3

1-3

None or any

BM 5%-9% or PB 2%-4%,
no Auer rods

MDS-EB-2

0-3

1-3

None or any

BM 10%-19% or PB 5%19%
or Auer rods

-with 1% blood blasts

1-3

1-3

None or any

BM <5%, PB =1%,
no Auer rods

- with single lineage dysplasia and pancytopenia

1

3

None or any

BM <5%, PB <1%,
no Auer rods

-based on defining
cytogenetic abnormality

0

1-3 ,

15%

BM <5%, PB <1%,
no Auer rods

Refractory cytopenia of
childhood

1-3

1-3

None

BM <5%, PB <2%

BM < 5%, PB < 1%, no
Auer rods

MDS with ring
sideroblasts (MDS-RS)

MDS with excess blasts
(MDS-EB)

MDS, unclassifiable
(MDS-U)

Differential Diagnosis of MDS

1. Idiopathic cytopenia of undetermined significance

MDS must be distinguished from other entities that
may also present with cytopenias and/or dysplasia.
The following are the most common entities that
should be considered.

2. Acute myeloid leukemia
3. MDS/MPN syndromes
4. Aplastic anemia
13
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WHO Classification of Head and Neck
Tumours: An Update
Dr Nasir Ud Din
Histopathology

Introduction
The recent 4th edition of World Health
Organization (WHO) classification of head and
neck tumours (the so called “blue book”) was
published in 2017 after a decade. In this edition,
a number of significant changes made across
all tumour sites including introduction of new
entities. This paper summarizes important changes
in head and neck tumours.
Salivary Glands
Mammary analogue Secretory carcinoma
(MASC) was first described by Sakalova et al in
2010. This tumour was introduced in recent blue
book, but renamed it as “Secretory carcinoma”.
It has morphological and immunohistochemical
similarity to secretory carcinoma of breast. In the
past, this tumour was being diagnosed as “zymogenpoor acinic cell carcinoma”, low grade cribriform
cystadenocarcinoma and adenocarcinoma, NOS.
Most cases occur in parotid gland, but have
been reported in minor salivary glands as well.
Histologically, microcysts containing eosinophilic
secretions are characteristic. Tumour cells express
CK7, S-100 protein, and mammaglobin and harbours
t(12;15)(p13;q25) translocation resulting in ETV6NTRK3 fusion.
Polymorphous low grade adenocarcinoma has
been renamed as polymorphous adenocarcinoma
(PAC). The term low grade was omitted due to
aggressive behavior of some of these tumours.
PAC represents second most common intraoral
malignant salivary gland tumour. It typically
presents as painless mass of variable duration (from
few weeks to 40 years). The previously described
cribriform adenocarcinoma of Tongue/minor salivary
glands is now considered a feature within the PAC
morphological spectrum.
Sclerosing polycystic adenosis is a new benign
entity described. This is a rare lesion which most
commonly involves parotid gland, and histologically
resembles fibrocystic changes and sclerosing
14

adenosis of breast. Recurrence has been seen in 11%
of cases that are incompletely excised or multifocal.
Tumours of the Oropharynx (Base of Tongue,
Tonsils, Adenoids)
The changes for oropharyngeal lesions are dramatic
and significant, largely due to the growing impact of
high risk human papillomavirus (HPV).WHO has
divided tumours of the oral cavity and oropharynx
into separate chapters, classifies squamous cell
carcinomas (SCC) of the oropharynx on the basis
of HPV status, abandons the practice of histologic
grading for oropharyngeal SCCs that are HPV
positive, and recognizes small cell carcinoma of the
oropharynx.
Separation of Oropharyngeal and Oral Cavity
Tumours
Oral cavity proper is comprised of the lips, gingiva,
retromolar trigone, hard palate, buccal mucosa,
mobile tongue, and floor of the mouth. Oropharynx is
comprised of the palatine tonsils, soft palate, tongue
base (posterior to the circumvallate papillae), and
posterior pharyngeal wall. Although the oral cavity
and oropharynx form one continuous chamber lined
by an uninterrupted stratified squamous epithelium
and by historical convention have been lumped
together under the blanket term “oral” or “oral
cancer”, they are dissimilar in many important
respects.
Most notable is the presence of tonsillar tissue (i.e.
lingual and palatine tonsils) in the oropharynx, and
its absence in the oral cavity. The highly specialized
lymphoepithelium (i.e. reticulated epithelium) lining
the tonsillar crypts provides a more permissive
environment for HPV infection and HPV-driven
tumourigenesis, resulting in much higher rates of
HPV in SCCs of the oropharynx (OPSCC) than in
SCCs of the oral cavity.
Recent analyses of cancer registry data show
dramatic increases in incidence of oropharyngeal
carcinomas during the past 15–20 years in several
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parts of the world, even as the incidence of oral
cavity carcinomas has remained constant or declined
during the same period.
These HPV-positive OPSCCs have unique
demographic profiles, unique genetic features distinct
from typical head and neck SCCs, distinct clinical
& morphologic features, and have improved clinical
outcomes.
Table 1. Comparison of HPV-positive and HPV-negative oropharyngeal SCC

Characteristics

of squamous differentiation) defined by the presence
of “nuclear protein in testis”(NUT) gene (NUTM1)
rearrangement. It is a rare tumour with a median
age of 21.9 years. Most cases (65 percent) occur
in the nasal cavity & paranasal sinuses. Clinically,
it presents as a rapidly growing mass manifested
by nasal obstruction, pain & epistaxis. 50 percent
present with lymph node involvement or distant
metastatic disease. Prognosis is very poor. Median
survival rate 9.8 months.

HPV-Positive

HPV-Negative

Median age

50-56 years

60-70 years

Gender

M=F

M>F

Site

Base of Tongue, Palatine tonsil

Soft palate, pharyngeal wall

Risk factors

Sexual behavior

Smoking and alcohol use

Lymph node metastasis

Frequently cystic

Uncommonly cystic

Postulated origin

Reticulated epithelium of invaginated crypts

Surface epithelium

Dysplasia

Rare

Often present

Morphology

Commonly non-keratinizing

Conventional SCC

Grading

Not applicable

Applicable

Tumour stage at presentation

Often higher (more nodal metastasis)

Often lower

P16 immunostaining

Positive

Negative

Overall survival rate (3 years)

82%

57%

HPV-related Small Cell Neuroendocrine Carcinoma
Some small cell carcinomas of the oropharynx
represent HPV-positive squamous cell carcinomas,
which have undergone small cell transformation.
Like small cell carcinomas of the lung, these HPVpositive small cell carcinomas of the oropharynx are
associated with cigarette smoking, high grade cellular
features, expression of neuroendocrine markers, and
an aggressive clinical behavior including widespread
dissemination and poor survival.
Tumours of the Nasal Cavity, Paranasal Sinuses
and Skull Base
The sinonasal tract is the site of origin for a variety
of neoplasms. Three new, relatively well-defined
entities: NUT carcinoma, biphenotypic sinonasal
sarcoma and seromucinous hamartoma are included.
HPV-related carcinoma with adenoid cystic-like
features is provisionally listed as a subtype of nonkeratinizing SCC.
NUT Carcinoma, a.k.a NUT midline carcinoma is a
poorly differentiated carcinoma (often with evidence

Biphenotypic Sinonasal Sarcoma is a low grade
spindle cell sarcoma with distinctive histological,
immunohistochemical, and molecular features. It is
most frequently characterized by a recurrent PAX3MAML3 gene fusion. It predominantly affects
females with mean age of 52 years (range 24-85
years). The tumour typically involves multiple sites in
the sinonasal tract, in particular superior aspect of the
nasal cavity and ethmoid sinus. It is a slowly growing
tumour with invasion of local structures. Nearly 50
percent of patients experienced recurrence (as long as
nine years after initial treatment). Neither metastatic
disease nor death from disease has been reported.
Sinonasal Papillomas
Sinonasal (Schneiderian) papillomas are benign
neoplasms that arise in the sinonasal tract. The lesion
now regarded as sinonasal papilloma. A summary of the
3 types of sinonasal papillomas are tabulated below.
Conclusions
The new edition of the WHO Blue Book has arrived
with great anticipation. Much has changed in
15

Molecular
Aberrations

Risk of
Malignant
Transformation

Histological
Features

Location

Type

Association with
HPV
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Sinonasal
papilloma,
Inverted type

Lateral
nasal wall
& paranasal
sinuses

-Thickened epithelium, scattered mucus
cells or cysts, intraepithelial neutrophils,
micro abscesses.
-Epithelium variably squamous, squamoid/
transitional, or ciliated columnar
- Prominent downward growth of rounded,
elongated and anastomosing epithelial nests
from surface epithelium

5-15%

EGFR
mutations

Unclear
association

Sinonasal
papilloma,
exophytic type

Nasal
septum

-Thickened epithelium, scattered mucus
cells or cysts, intraepithelial neutrophils,
micro abscesses.
-Epithelium usually squamous, sometimes
squamoid/transitional.
-Broad, branching fronds of epithelium surrounding fibrovascular cores
- +/- koilocytes

Close to 0%

None
known

Most caused
by low-risk
HPV-types

Sinonasal
papilloma,
oncoytic type

Lateral
nasal wall
& paranasal
sinuses

-Thickened epithelium, scattered mucus
cells or cysts, intraepithelial neutrophils,
micro abscesses.
-Both inverted and exophytic growth
-Epithelium pseudostratified columnar
epithelium cells, with abundant granular
cytoplasm & small hyperchromatic nuclei

4-17%

KRAS
mutations

No
association

head and neck pathology in the past 10–12 years,
including a great deal in oropharyngeal tumours.
With the alarming upsurge of HPV-positive OPSCC,
the WHO has responded by creating a separate
oropharynx chapter and separating OPSCCs on
the basis of HPV status. Oropharyngeal small
cell carcinomas can be HPV-positive and must be
distinguished from SCC since they appear to be
aggressive tumours, regardless of HPV status.

Polymorphous adenocarcinoma will be the blanket term
for tumours formerly designated as polymorphous low
grade adenocarcinoma or cribriform adenocarcinoma of
Tongue/minor salivary glands. Specific grade has been
removed from the PAC.
Secretory carcinoma is introduced which has
been previously called zymogen-poor acinic cell
carcinoma or adenocarcinoma, NOS.

Plasma Metanephrines in Diagnosis of
Pheochromocytoma
Dr Syed Bilal Hashmi
Chemical Pathology

The terms pheochromocytoma and paraganglioma
are often used interchangeably because
morphologically and functionally these entities are
the same. Paragangliomas that arise in the adrenal
medulla are defined as pheochromocytomas,
and those outside the adrenal gland are called
16

paragangliomas. Common symptoms of
pheochromocytomas are episodic and sudden onset
of severe headaches, sweating, and abdominal
pain, high blood pressure that may be resistant to
conventional medications, rapid heart rate, irritability
and anxiety. These tumours produce excess
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hormones called catecholamines, which are broken
down to metanephrine.
The Endocrine Society, European Society of
Endocrinology, and American Association for
Clinical Chemistry recommends that for patients
who are being evaluated because of strong risk
factors for a catecholamine-secreting tumour,
such as those with known mutations for familial
pheochromocytoma, the initial biochemical testing
for pheochromocytomas and paragangliomas should
include measurements of plasma free metanephrine
or urinary fractionated metanephrine. Genetic
testing in all patients is recommended. Computed
tomography is suggested for initial imaging, but
magnetic resonance is a better option in patients
with metastatic disease or when radiation exposure
must be limited. Diagnostic approach to evaluate a
patient suspected of catecholamine secretion tumour
is shown in figure 1.

tumours derived from neural crest cells. This test
is somewhat more sensitive than 24-hour urinary
fractionated metanephrine, likely because even
small pheochromocytomas may continually leak
metanephrine even if they are not actively secreting
catecholamines. The test is also appropriate for
individuals who are unable to perform an accurate
24-hour urine collection, such as young children.
All patients with positive test results should receive
appropriate follow-up according to the extent of
increased values and clinical presentation.
Note: There are some substances that can falsely
increase the plasma metanephrine levels. So these
should be avoided before getting tested for plasma
metanephrine levels. These include:
l

Tyrosine rich foods such as banana, cheese, 		
caffeine, citrus fruits or nuts.

Plasma
Metanephrines
Normal

Elevated

3-4 times URL
(Tumor
possible)

Tumor
unlikely

>4 times URL
(Tumor
probable)

Recent Plasma
Metanephrines
Results
elevated

Normal

Tumor
unlikely

Figure 1: Diagnostic approach to evaluate a patient suspected of catecholamine secretion tumour

Tumor
Possible
Clonidine
suppression
test
l

(Source: http://www.snp.com.au/media)

The plasma free metanephrine test measures the
amount of metanephrine and nor-metanephrine
in the blood. Measurements of plasma free
metanephrine are used for initial biochemical testing
for diagnosis of pheochromocytoma and other

l
l

Medications such as MAO inhibitors, tricyclic
antidepressants, lidocaine and clonidine etc.
Sleep medications, anxiolytics and 			
antihistamines.
Alcohol and smoking.
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Megaloblastic Anemia
Dr Natasha Ali
Hematology & Transfusion Medicine

This is a group of anemias in which the erythroblasts
in the bone marrow show a characteristic abnormality
i.e maturation of nucleus being delayed relative to that
of cytoplasm due to defective DNA synthesis.

Table 2. Causes of folate deficiency.

Causes of Megaloblastic Anemia
l

Cobalamine( vitamin B12)

Cobalamin is synthesized solely by microorganisms.
only source for humans is food of animal origin. Body
stores are of the order of 2–3 mg and are sufficient for
three–four years if supplies are completely cut off.
Table 1. Causes of cobalamin deficiency causing megaloblastic
anaemia.

of intrinsic factor (IF) due to gastric atrophy. The
disease occurs more commonly than by chance in
close relatives, in subjects or families with other
organ-specific autoimmune diseases of the thyroid,
adrenal or parathyroid, in those with premature
greying, blue eyes and vitiligo, and in persons of
blood group A.
Clinical Feature of Megaloblastic Anemia
l

Folate

Most foods contain some folate. The highest
concentrations are found in liver and yeast (>200 μg per
100 g), spinach, other greens and nuts (>100 μg per 100
g). Total body folate in the adult is about 10 mg. Stores
are only sufficient for about 4 months in normal adults,
so severe folate deficiency may develop rapidly.
l

Pernicious Anaemia

Pernicious anaemia(PA) is defined as severe lack
18

l
l
l
l
l
l
l

Shortness of breath.
Muscle weakness / Neuropathy.
Abnormal paleness of the skin.
Glossitis (swollen tongue)
Loss of appetite/weight loss.
Diarrhea.
Nausea.

Laboratory Findings
CBC: Complete blood count report macrocytic
anemia with other cytopenias. MCV is usually more
than 96fl and can reach upto 140fl.
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Peripheral film : Peripheral film shows typical
oval macrocytes and hypersegmented neutrophils.
Anisocytosis, poikilocytosis, polychromasia and
Nucleated red blood cells seen. Erythrocytes may
contain cabot rings.

and show open, fine, lacy primitive chromatin
pattern but normal cytoplasmic hemoglobinization.
Giant and abnormally shaped metamyelocytes are
characteristic.
Other investigations
Serum vitamin B12 levels : low levels less than
B12<150ng/l .
Serum or erythrocyte folate levels: low levels of
RBC folate confirm diagnosis.
Serum holotranscobalamine : early marker of B12
deficiency <25pmol/L.
Methylmalonic acid (MMA) and homocysteine
levels are raised.
Serum lactic dehydrogenase (LDH ) is raised.

Figure 1: Peripheral film in a patient with megaloblastic anemia shows
Oval macrocytes and a hypersegmented neutrophil in center.

Bone marrow aspiration: The bone marrow is
usually hypercellular and erythroblasts are large

Differential Diagnosis
Conditions in which macrocytosis or
hypersegmented neutrophils may occur in the
absence of megaloblastic anaemia.

Figure 2: Megaloblastic changes in the bone marrow in a patient with
severe megaloblastic anaemia. (a-c) Erythroblasts showing fine open
stippled (primitive) appearance of the nuclear chromatin even in late
cells (pale cytoplasm with some haemoglobin formation). (d) Abnormal
giant metamyeiocytes and band forms.

Aplastic Anemia
Dr Sana Brohi
Haematology & Transfusion Medicines

Aplastic Anemia (AA) refers to pancytopenia in
association with bone marrow hypoplasia/ aplasia,
in absence of an abnormal infiltrate and with no

increase in reticulin. In aplastic anemia, there must
be at least two of the following: (i) hemoglobin
below 100 g/l, (ii) platelet count below 50 X 109/L
19
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and (iii) neutrophil count below 1.5 X 109/L. AA
is a rare disorder (two to four per million per year)
that affects men and women equally, and it is lifethreatening if untreated. AA is associated with loss
of hematopoietic stem cells (HSCs) due to direct
stem cell injury, viral suppression, autoimmune
mechanisms, and inherited or acquired clonal/genetic
abnormalities. Autoimmune damage to HSCs is an
important contributor to most cases of AA in which
no underlying cause is clearly identifiable (idiopathic
AA). There are two types of AA: (i) Inherited
aplastic anemia/bone marrow failure, (ii) Acquired
aplastic anemia.
Laboratory Tests to Confirm Diagnosis
Full blood count (pancytopenia with
reticulocytopenia), blood film examination, liver
function tests, vitamin B12, and folate, virology,
antinuclear antibody and dsDNA, bone marrow
examination shows hypocellular/aplastic bone

marrow biopsy, morphologically normal residual
hematopoietic cells, and no infiltration with
malignant cells or fibrosis; the marrow space is
composed mostly of fat cells and marrow stroma.
Tests to detect an associated abnormal clone,
Cytogenetic studies on bone marrow, CD55/59
screen for paroxysmal nocturnal hemoglobinuria.
For purposes of risk stratification and selection of
therapy, AA is classified according to the following
criteria:
Severe AA — Diagnosis of severe aplastic anemia
(SAA) requires both of the following criteria: (i)
Bone marrow cellularity <25 percent, or 25 to 50
percent with <30 percent residual hematopoietic
cells. (ii) At least two of the following:
1. neutrophils <0.5 X 109 /L
2. platelets <20 X 109 /L
3. reticulocytes < 60 X 109 /L
Very severe AA — As for severe AA but neutrophils
<0.2 X 109 /L.
Non-severe AA — Patients not fulfilling the criteria
for severe or very severe AA.
Differential Diagnosis

Figure 1: Bone marrow biopsy in aplastic anemia. There are virtually no
hematopoietic cells, and the marrow space consists of fat and stroma.
Courtesy of Stanley L Schrier, MD.

Other causes of pancytopenia, such as megaloblastic
anemia, bone marrow infiltration (eg, myelofibrosis,
various cancers), sequestration/redistribution (eg,
hypersplenism), and certain myeloid malignancies
(eg, myelodysplastic syndrome [MDS], acute
myeloid leukemia [AML]),T-Large granular
lymphocyte leukemia, paroxysmal nocturnal
hemoglobinuria (PNH).

Transfusion Associated Circulatory Overload
(Taco): A Severe But Preventable Transfusion
Reaction
Dr Nazish Sana and Dr Mohammad Shariq Shaikh
Hematology and Transfusion Medicine

Transfusion associated circulatory overload is a
transfusion reaction in which pulmonary edema
develops primarily due to volume excess or
circulatory overload. According to Serious Hazards of
Transfusion (SHOT) report 2016, it has been reported
20

as one of the major causes of transfusion associated
mortality. Reports of TACO increased steadily, from
six to ninety six; deaths increased from one to twelve;
and instances of major morbidity increased from three
to thirty four from 2007 to 2017.
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Risk Factors
Risk factors include
l
Extremes of age (e.g., <3 years, >60 years)
l
Low body weight
l
Small stature
l
Faster blood product infusion rate
l
Pre-existing cardiac disease
l
Pre-existing renal dysfunction
l
Pulmonary disease
l
Hypoalbuminemia
l
Positive fluid balance
Clinical Presentation
TACO presents as following sign/symptoms during
or within six hours of completing a transfusion.
l
Acute respiratory distress, hypoxia, dyspnea,
		or tachypnea
l
Tachycardia
l
Increased blood pressure
l
Acute or worsening pulmonary edema
l
Evidence of positive fluid balance e.g. wide
		 pulse pressure, and/or jugular venous
		distension
Differential Diagnoses
l

l

l

Transfusion-related acute lung injury
(TRALI) is the top most differential
diagnosis of TACO. Differentiating features
include hypertension, raised jugular venous
pressure, raised pulmonary arterial pressure
to >18mmHg, positive fluid balance, raised
brain natriuretic peptide levels (>1200pg/ml)
and significant response to diuretic in TACO
as compared to TRALI.
Transfusion-associated dyspnea – Transfusionassociated dyspnea is acute respiratory
distress occurring within 24 hours of
cessation of transfusion and do not meet the
criteria for other transfusion reactions.
Anaphylactic transfusion reactions –
Anaphylactic transfusion reactions occur
when IgA-containing blood component
transfused to IgA-deficient individual who
has pre-formed antibodies to IgA. Unlike
TACO, anaphylactic transfusion reactions

occur at the initiation of the transfusion
(before significant volume is infused) with
no symptoms of circulatory overload.
Management
It includes immediately stopping the transfusion,
fluid mobilization with diuretics, supplementary
oxygen, and assisted ventilation if indicated.
Prevention
Avoiding unnecessary transfusion.
Limiting transfusion of RBCs to two units
		 per day in patients who are not actively 		
		bleeding.
l
Avoiding overly rapid transfusion rates and
		 reducing the volume of the transfusion.
l
A transfusion rate of approximately 2.0 to
		 2.5 mL/kg per hour is reasonable
l
Patients with underlying risk factor for 		
		 TACO can be safely transfused at a rate of
		 1 mL/kg per hour and monitored more
		 closely during the transfusion for signs and
		symptoms of TACO.
l
Diuresis may be given before or during
		 transfusion in selected individuals e.g.
		 receiving chronic diuretic therapy, heart
		 failure, and with a history of TACO.
l
l

AKUH Experience
A total of eight cases of TACO have been notified
from January 2016 till September 2017. Significant
underlying comorbidities like renal disease, heart
disease, hypoalbuminemia, positive fluid balance
and underlying pulmonary edema were identified
as predisposing factors in all patients. Five patients
required prolonged hospital/special care unit stay
whereas, 2 patients also required Bi-level Positive
Airway Pressure (BiPAP) support.
Recommendations
According to Annual SHOT report 2016, whenever
possible a formal pre-transfusion risk assessment for
TACO should be performed as follows.

21
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TACO Checklist

Red Cell Transfusion
for Non-bleeding Patients
Does the patient have a diagnosis of ‘heart
failure’ congestive cardiac failure (CCF),
severe aortic stenosis, or moderate to severe
left ventricular dysfunction?
Is the patient on a regular diuretic?

Is the patient known to have pulmonary
oedema?
Does the patient have respiratory symptoms
of undiagnosed cause?

Is the fluid balane clinically significantly
positive?
Is the patient on concomitant fluids (or has
been in the past 24 hours)?
Is there any peripheral oedema?
Does the patient have hypoalbuminaemia?
Does the patient have significant renal
impairment?

If ‘yes’ to any of these questions

1
2
3

l

Review the need for transfusion (do the
benefits outweigh the risks)?

l

Can the transfusion be safely deferred
until the issue can be investigated,
treated or resolved?

l

Consider body weight closing for red
cells (especially if low body weight)
Transfuse one unit (red cells) and review
symptoms of anaemia
Measure the fluid balance
Consider giving a prophylactic diuretic
Monitor the vital signs closely,
including oxygen saturation

l
l
l
l

Due to the differences in adult and neonatal physiology, babies may have a different
risk for TACO. Calculate the dose by weight and observe the notes above.
Conclusion
Transfusion associated circulatory overload is serious

but preventable transfusion reaction. Appropriate
pre-transfusion assessment in each patient is
important in ensuring safe blood transfusion practice.

Meeting Report: A Zoom Web Conferencing
Session – Virtual Meet Up of Chemical
Pathology Fraternity Across The Country and
Discussion Regarding The Expected Changes
in Upcoming Exam Patterns
Dr Sibtain Ahmed
Chemical Pathology

On April 26, 2018 in line with medical laboratories
professionals’ week, an interactive session was
organized by the section of Chemical Pathology,
Department of Pathology and Laboratory Medicine,
22

the Aga Khan University (AKU) in collaboration
with Pakistan Society of Chemical Pathology
(PSCP). This was a ‘first of its kind meeting’
conducted using a virtual platform ensuring
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Picture 1: Participants From Karachi gathered at Aga Khan University.

Picture 3: Chemical Pathology faculty answering queries of participants
during the zoom session

maximum participation from Chemical Pathology
training centers across the country. Chemical
Pathology group from Karachi gathered at AKU with
participation from Sindh Institute of Urology and
Transplant, PNS Shifa, Liaquat National Hospital,
Ziauddin University Hospital, Dow University
of Health Sciences and Indus Hospital. A virtual
podium was utilized for the meeting based on ZOOM
that enabled participation from various centers
across the country specifically SMDC Lahore, AFIP
Rawalpindi, CMH Quetta, QAMC Bahawalpur,
SZMC Rahim Yar Khan and RMIT Peshawar. During
the two hour session, almost all the recognized
centers across Pakistan (Karachi, Rawalpindi,
Lahore, Peshawar, Quetta, Bahawalpur and Rahim
Yar Khan) were on board.

the significance of such collaborative activities and
its value for the young blood. His talk was followed
by an introduction from all the attendees. The next
talk was by Prof Dr. Aamir Ijaz who shed light on
the overview of curriculum and assessment in IMM
of Pathology. His session was of utmost importance
for all the trainees and as expected was followed
by a variety of questions. The next dialogue was by
Dr Adnan Mustafa Zuberi, he presented an update
of expected changes in FCPS-II examination of
Chemical Pathology. This was a very informative
presentation for the trainees especially those
approaching the upcoming examination and was
further supported by key tips from Dr. Imran Siddiqui
and Dr. Aamir Ijaz.

Picture 2: Participants from other cities of Pakistan connected via Zoom.

The ideology behind this activity was to develop
connections of Chemical Pathology trainees from
across Pakistan with supervisors and discuss the
expected changes in upcoming exam patterns
including intermediate module (IMM) and FCPS part
2. Maximum time was spent in discussions on the
overview of curriculum and assessment in IMM.
The activity was officially called on by a welcome
note by Prof Dr. Imran Siddiqui, one of the pioneers
of Chemical Pathology at AKU. He emphasized on

Dedicated assessment and curriculum allied sessions
were followed by a discussion by Prof Dr. Asma
Shaukat who gave vital tips and instructions for trainees
to successfully ace the residency period and complete
their requirements to be eligible for the exit exam
in due course of time. Subsequently Brig Dr. Brig.
Muhammad Aamir delivered a talk on opportunities
for trainees in upcoming cities of Pakistan. He
discussed regarding the constraints faced by trainees
in far flung areas and how to overcome them with the
help of bigger established centers. The last talk of the
meeting was by section head of Chemical Pathology
AKU, Dr. Aysha Habib Khan who suggested young
Chemical Pathologists to explore broader horizons in
future specially focusing on metabolic medicine as
subspecialty training. Lots of questions were raised in
the two hours networking session by the trainees and
were responded by the panelists.
The event came to conclusion with a vote of thanks
from Dr. Aysha Habib Khan. She appreciated event
organizers Dr. Hafsa Majid and Dr. Sibtain Ahmed
for this initiative and encouraged the participants
to utilize such platform in future as well for the
maximum benefits of our fraternity.
23

hospitals.aku.edu/Karachi/clinical-laboratories

